Search results: (10000)
News Risk Factors and Therapy of Chronic Leg Ulcers Lasting More Than 6 Months
The therapy of chronic leg ulcers in diabetics continues to be a significant challenge for attending physicians and surgeons. Authors of a recently published study have addressed the risk factors, clinical symptoms, and, last but not least, the therapy outcomes of chronic leg ulcers lasting more than 6 months.
News Impact of Oral Antidiabetics on Heart Failure
Diabetes mellitus is primarily perceived as a risk factor for ischemic heart disease and general atherosclerotic complications. However, an equally significant problem is the association between diabetes and heart failure. This hypothesis is confirmed by the VALUE study, which primarily focused on arterial hypertension. Its results show that individuals with diabetes had a higher risk of heart failure compared to the risk of acute myocardial infarction.
News Impact of Vitamin D Deficiency on Inflammatory Cytokine Concentrations in Patients with Diabetic Foot Syndrome
Vitamin D deficiency is relatively common in the population. Vitamin D plays an important role, among other things, in the functioning of the immune system. The aim of the presented study was to determine whether there is a connection between vitamin D levels and the profile of inflammatory cytokines in patients with wound infections in the context of diabetic foot syndrome.
News Dysregulation of microRNA Expression After Treatment with Anti-EGFR Antibodies
A team of researchers from Plzeň decided to verify whether treatment with anti-EGFR antibodies changes the expression of selected microRNAs in patients with metastatic colorectal carcinoma (mCRC). They have just published their findings in the autumn issue of the journal Cancer Genomics Proteomics.
News Panitumumab in 1st Line in Older Patients – Results of the PANDA Study
The phase II PANDA study evaluated the regimens FOLFOX + panitumumab versus 5-FU + panitumumab in the 1st line treatment of patients with wt-RAS/BRAF metastatic colorectal cancer (mCRC).
News Two Is Not Enough: Efficacy of Alemtuzumab in Subsequent Cycles
The goal of the recent pooled analysis of the CARE-MS and TOPAZ study results published in the journal Multiple Sclerosis was to evaluate the efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis (RRMS) who received alemtuzumab in additional cycles beyond the first 2 cycles.
News Experiences with AHA in Two Czech Centers and Risk Factor Evaluation
This summer, the journal Haemophilia published the results of an analysis of data from a relatively large Czech cohort of patients with acquired hemophilia A (AHA). The goal was to identify risk factors associated with early death and AHA relapse. Additionally, the authors addressed the question of the effect of higher doses of corticosteroids on treatment outcomes and patient mortality.
News Does Ixekizumab Have Long-term Effects on Improving Psoriatic Arthritis Symptoms?
The extension of the SPIRIT-P2 study brought results of ixekizumab in patients with psoriatic arthritis (PsA) after 3 years of use. The data below were presented as a poster presentation at the annual congress of the European League Against Rheumatism (EULAR), which was held virtually in June 2020.
News Did the Extension of the TOWER Study Confirm the Position of Teriflunomide?
The results of the TOWER study extension were published this August in the prestigious journal Multiple Sclerosis and Related Disorders. So, how did teriflunomide fare in this recent evaluation for the treatment of relapsing-remitting multiple sclerosis?
News COVID-19: Specifics of Care for Individuals with Congenital Bleeding Disorders
The COVID-19 pandemic has significantly impacted nearly all medical fields. Alongside direct care focused on seriously ill patients, the pandemic also affects the care of chronic patients, including those with hemophilia. However, there is currently not much specific data available regarding experiences with COVID-19 in patients with hemophilia. The specifics of congenital bleeding disorders, especially in relation to the severe course of COVID-19, are discussed by Italian authors in their article published in the journal Seminars in Thrombosis and Hemostasis.
News Safety Profile of Antiemetic Therapy in Patients Preparing for Hematopoietic Stem Cell Transplantation
An observational study conducted at a university clinic in Barcelona investigated the safety of the fixed combination of palonosetron and netupitant in patients preparing for hematopoietic stem cell transplantation.
News Brigatinib vs. Crizotinib in the Treatment of ALK-Positive NSCLC – Results of the Second Interim Analysis of the ALTA-1L Study
The anaplastic lymphoma kinase inhibitor brigatinib demonstrated superiority over crizotinib in the first interim analysis of the ALTA-1L study in terms of progression-free survival and improvement in health-related quality of life in patients with non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangement. The second interim analysis results published in 2020 confirm these primary findings.
News Self-Administration of Romiplostim in Chronic Immune Thrombocytopenia: Analysis of 3 Studies
A post hoc analysis of 3 clinical studies showed that in adult patients with chronic immune thrombocytopenia (ITP), self-administration of romiplostim achieves comparable efficacy and safety as when the drug is administered by a healthcare professional.
News The Role of the Physiotherapist in the Management of Hemophilia – Defining a New Normal
Historically, the role of physiotherapy in hemophiliacs was primarily to assist patients who developed severe hemophilic arthropathies resulting from recurrent untreated or inadequately treated bleeding. Today, it has also shifted to prevention as such, although it still plays a role in significant joint bleeding or when a hemophiliac needs to undergo surgery.
News Improvement of Physical Functions in Patients with COPD in Routine Clinical Practice Using the Fixed Combination of Tiotropium/Olodaterol
The increase in exercise capacity using the fixed combination of tiotropium and olodaterol in the Respimat inhaler has already been demonstrated in clinical studies for patients with chronic obstructive pulmonary disease (COPD). Italian authors evaluated its benefit under real-world conditions and also focused on patient satisfaction with the inhaler.
News Thromboprophylaxis with Enoxaparin Reduces Mortality in Patients Hospitalized with COVID-19
Severe acute respiratory syndrome caused by COVID-19 is associated with a hypercoagulable state and an increased risk of thrombotic events. Since the beginning of the pandemic, thromboprophylaxis has been recommended for these patients despite initial insufficient evidence. In the fall of 2020, an observational study was published confirming the beneficial effect of enoxaparin on reducing mortality and the risk of ICU admission in patients with severe COVID-19.
News Tolerability and Efficacy of Eye Drops with and without Preservatives − A Comparison in Routine Clinical Practice
Insufficient patient compliance due to intolerance of the ocular preparation is a major reason for changing treatment, such as switching to preservative-free drops. The aim of the international prospective and observational study was to assess the efficacy and local tolerability within a one-year therapy of preservative-free latanoprost compared to drops containing preservatives and to determine patient satisfaction at the midpoint of treatment. During the monitoring, 3 examinations were planned: one at the study entry and two follow-up visits (at 6 and 12 months).
News In vivo monitoring of corneal changes in patients treated with and without preservative-containing glaucoma medications
A study published last year by Italian authors monitored structural changes in the corneas of patients treated with preservative-free glaucoma medication for 3 years using confocal microscopy and compared them with changes observed in patients treated with preservative-containing medications.
News Aclidinium bromide improves the quality of life for COPD patients
The ON-AIR study conducted in real practice demonstrated the benefits of aclidinium bromide for the quality of life of patients with chronic obstructive pulmonary disease (COPD). It also assessed the impact of treatment on the severity of nocturnal and morning symptoms and their impact on daily activities.
News Incidence of Allergic Diseases in Children Probably Unrelated to Air Pollution
A recently published extensive meta-analysis of 7 cohorts of children aged 4 and 8 from 5 European countries investigated the relationship between air pollution at the child's place of residence and the incidence of allergic eczema, rhinoconjunctivitis, or asthma.
News How to Communicate and Receive an Oncological Diagnosis
Communicating the truth about a patient's health condition does not have a very long tradition in the Czech Republic. The Czech healthcare system only began to emphasize this aspect, that is, honest and open communication between doctor and patient, several years after the Velvet Revolution.
News Idarucizumab reverses the anticoagulant effect of dabigatran even in patients with impaired renal function – clinical practice commentary
Along with the results of a subanalysis of the RE-VERSE AD study, which demonstrated the efficacy of idarucizumab in reversing the anticoagulant effect of dabigatran regardless of the level of renal function impairment, the October issue of the Journal of the American College of Cardiology also featured an editorial commentary by Californian cardiologists on its conclusions.
News Can NOACs 'Compete' with Well-Managed Warfarin Treatment? Retrospective Data from Swedish Registers
The efficacy and safety of new oral anticoagulants (NOACs) in stroke prevention in atrial fibrillation have been proven by numerous studies. The quality of warfarin treatment, assessed by the 'time in therapeutic range' (TTR), ranged between 55% and 65% in these studies. The work of Swedish authors provides a comparison of patients treated with NOACs to a group on warfarin whose average TTR reached 70%.
News Metformin in New European Guidelines for Treating Patients with Diabetes and Cardiovascular Disease
The position of metformin has changed in the guidelines for the treatment of prediabetes and type 2 diabetes in individuals with cardiovascular (CV) disease, issued by the European Society of Cardiology (ESC) in collaboration with the European Association for the Study of Diabetes (EASD) in 2019. The 2019 EASD recommendations differ somewhat, thus we provide the following updated summary.